ADC Therapeutics SA
ADC Therapeutics SA's revenue rose 14.8% to $81 million in fiscal 2025. Its operating margin was −149.3%, up from −184.4% a year earlier. Free cash flow was −$141 million. The diluted share count rose 30.8%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What ADC Therapeutics SA does
ADC Therapeutics is a biotechnology company based in Lausanne, Switzerland, with operations in New Jersey. It makes antibody drug conjugates, which are medicines that join an antibody to a cell-killing drug so that the drug is delivered to cancer cells. Its one approved product is Zynlonta, aimed at a protein called CD19.
Zynlonta has accelerated approval from the U.S. FDA, and conditional approval in the European Union, China and Canada, to treat large B-cell lymphoma, a blood cancer, in patients whose disease has returned or not responded after two or more earlier treatments. The company sells it itself and is running trials to use it earlier in treatment and for other lymphomas, in combination with other drugs.
It also has other drug candidates in earlier stages. It relies on outside contract manufacturers to make its medicines.
Its biggest risks, as it describes them
- Its debt and the loan's restrictive terms could hurt its finances.
- A royalty agreement with HCR cuts the cash it keeps from Zynlonta sales.
- It may not finish clinical trials on time, or at all.
- Its results swing with non-cash charges and with exchange rates.
- Its reliance on Zynlonta, a single approved product.
Income statement
ADC Therapeutics SA lost money in fiscal 2025: a net loss of $143 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 466 | 326 | 279 | 251 | 261 |
| Debt incl. finance leases | 94 | — | — | — | — |
| Net debt (negative means net cash) | −373 | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.6x | — | — | — | — |
| Interest coverage | −14.3x | −3.4x | −3.6x | −2.6x | −2.4x |
| Current ratio | 7.1x | 5.3x | 5.0x | 3.6x | 4.4x |
| Quick ratio | 7.0x | 5.2x | 4.7x | 3.6x | 4.3x |
Cash flow
Projections
Project ADC Therapeutics SA's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought ADC Therapeutics SA shares on the open market, and 1 insider sold $19.6 million.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Apr 2, 2026 | RedCo II Master Fund L.P.10% owner | Sold | 5,163,997 | $3.28 | $16.9 million | Form 4 |
| Apr 1, 2026 | RedCo II Master Fund L.P.10% owner | Sold | 331,782 | $3.80 | $1.3 million | Form 4 |
| Mar 31, 2026 | RedCo II Master Fund L.P.10% owner | Sold | 384,636 | $3.75 | $1.4 million | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −242.1% | −174.2% | −159.0% |
| Altman Z'' | −10.76 | −13.96 | −14.62 |
| Accruals ratio | −28.7% | −10.1% | −0.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Fail | Pass |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | — | — | — |
Compare
Put ADC Therapeutics SA side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| ADC Therapeutics SA | FY25 | 14.8% | −149.3% | −173.8% | — | — | — | |
| MeiraGTx | FY25 | 144.6% | −130.2% | −61.7% | — | — | 3 | Compare |
| 4D Molecular Therapeutics | FY25 | 230,194.6% | −187.2% | −128.7% | — | — | — | Compare |
| CytomX Therapeutics | FY25 | −44.8% | −29.4% | −99.5% | — | — | — | Compare |
| Autolus Therapeutics | FY25 | 644.9% | −358.9% | −401.4% | — | — | 3 | Compare |
8 years of figures
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 1 | 2 | 0 | 34 | 210 | 70 | 71 | 81 |
| Revenue growth | — | 105.3% | −100.0% | — | 518.9% | −66.9% | 1.8% | 14.8% |
| Gross profit | — | 2 | 0 | 32 | 207 | 67 | 65 | 76 |
| Research and development | 118 | 108 | 142 | 158 | 186 | 127 | 110 | 104 |
| Operating income | −126 | −119 | −219 | −262 | −123 | −166 | −131 | −122 |
| Net income | −123 | −116 | −246 | −230 | −157 | −240 | −158 | −143 |
| Diluted EPS (US$) | −2.64 | −2.36 | −3.77 | — | −2.01 | −2.94 | −1.62 | −1.12 |
| Diluted shares (millions) | 47 | 49 | 65 | 77 | 78 | 82 | 97 | 127 |
| Cash flow | ||||||||
| Cash from operations | −121 | −122 | −169 | −233 | −138 | −119 | −124 | −141 |
| Capital expenditure | 1 | 0 | 1 | 3 | 1 | 3 | 1 | 0 |
| Free cash flow | −122 | −122 | −170 | −237 | −139 | −122 | −125 | −141 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 1 | 38 | 60 | 49 | 14 | 7 | 7 |
| Balance sheet at fiscal year end | ||||||||
| Cash and short-term investments | 139 | 116 | 439 | 466 | 326 | 279 | 251 | 261 |
| Debt incl. finance leases | — | 0 | 38 | 94 | — | — | — | — |
| Total assets | — | 138 | 514 | 618 | 491 | 355 | 322 | 323 |
| Total liabilities | — | 26 | 178 | 452 | 411 | 503 | 525 | 509 |
| Shareholders' equity | 126 | 111 | 336 | 154 | 80 | −148 | −203 | −186 |
| Margins and ratios | ||||||||
| Gross margin | — | 100.0% | — | 95.9% | 98.4% | 96.4% | 91.6% | 92.9% |
| Operating margin | −11,047.5% | −5,102.5% | — | −771.6% | −58.8% | −238.6% | −184.4% | −149.3% |
| Net margin | −10,797.9% | −4,977.9% | — | −678.2% | −74.9% | −345.1% | −222.8% | −175.3% |
| Free cash flow margin | −10,728.6% | −5,211.1% | — | −698.2% | −66.2% | −175.2% | −176.0% | −173.8% |
| Rule of 40 (growth + FCF margin) | — | −5,105.8% | — | — | 452.7% | −242.1% | −174.2% | −159.0% |
| Return on capital | — | — | — | — | — | — | — | — |
| Return on equity | — | — | −110.3% | −94.0% | −134.6% | — | — | — |
| Return on assets | — | — | −75.6% | −40.6% | −28.3% | −56.8% | −46.6% | −44.2% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — |